key: cord-0779238-8t6md5wu authors: Prasansuklab, Anchalee; Theerasri, Atsadang; Rangsinth, Panthakarn; Sillapachaiyaporn, Chanin; Chuchawankul, Siriporn; Tencomnao, Tewin title: Anti-COVID-19 drug candidates: A review on potential biological activities of natural products in the management of new coronavirus infection date: 2020-12-29 journal: J Tradit Complement Med DOI: 10.1016/j.jtcme.2020.12.001 sha: 06633daf67da5f0be935ef9218ea8720690e9306 doc_id: 779238 cord_uid: 8t6md5wu BACKGROUND AND AIM: The novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now become a worldwide pandemic bringing over 71 million confirmed cases, while the specific drugs and vaccines approved for this disease are still limited regarding their effectiveness and adverse events. Since virus incidences are still on rise, infectivity and mortality may also rise in the near future, natural products are highly considered to be valuable sources for the discovery of new antiviral drugs against SARS-CoV-2. This present review aims to comprehensively summarize the up-to-date scientific literatures on biological activities of plant- and mushroom-derived compounds relevant to mechanistic targets involved in SARS-CoV-2 infection and inflammatory-associated pathogenesis, including viral entry, replication and release, and the renin-angiotensin-aldosterone system (RAAS). EXPERIMENTAL PROCEDURE: Data were retrieved from a literature search available on PubMed, Scopus and Google Scholar databases and collected until the end of May 2020. The findings from in vitro cell and non-cell based studies were considered, while the results of in silico studies were excluded. RESULTS AND CONCLUSION: Based on the previous findings in SARS-CoV studies, except in silico molecular docking analysis, herein, we provide a total of 150 natural compounds as potential candidates for development of new anti-COVID-19 drugs with higher efficacy and lower toxicity than the existing therapeutic agents. Several natural compounds have showed their promising actions on multiple therapeutic targets, which should be further explored. Among them, quercetin, one of the most abundant of plant flavonoids, is proposed as a lead candidate with its ability on the virus side to inhibit SARS-CoV spike protein-angiotensin-converting enzyme 2 (ACE2) interaction, viral protease and helicase activities, as well as on the host cell side to inhibit ACE activity and increase intracellular zinc level. On 31 December 2019, several cases of pneumonia were reported in Wuhan, the epicenter of the outbreak in Hubei province of China. 1 The novel coronavirus was identified as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) which causes Coronavirus Disease 2019 (COVID-19) pandemic. 2, 3 From the time of emergence until present, COVID-19 has spread worldwide in which a total of over 71 million confirmed cases with over 1.6 million death tolls has been reported by the World Health Organization (WHO). The COVID-19 positive cases continue rising and is widely distributed throughout the world with the prevalence ranging from highest in America, followed by Europe and South-East Asia, and lowest in Western Pacific region. Asymptomatic patients and patients with mild symptoms can be recovered under home care and isolation while patients with severe complications including acute respiratory distress syndrome (ARDS) require intensive care unit (ICU) which involves oxygen therapy. 4, 5 Currently, there is scant evidence from clinical trials for WHO to approve any standard drugs or vaccines as several trials have failed due to efficacy and safety concerns. 6, 7 Natural compounds from plant and fungi sources have been recognized in their antiviral properties with numerous mechanisms to prevent infection and strengthen host immunity. 8, 9 Herein, we reviewed potential antiviral compounds with multiple targets of action relating to coronaviruses including inhibiting of viral entry, replication and release, and compounds targeting renineangiotensinealdosterone system (RAAS) which exhibit promising effects against the disease. We also proposed future perspectives in adopting natural compounds to combat against the COVID-19. Presently, there is no clinically approved therapeutics for treating COVID-19, while the rapid human-to-human transmission of this viral infection has expanded worldwide. As the efficacy and safety of natural products on the treatment of a number of viruses including SARS-CoV and Middle East Respiratory Syndrome Coronavirus (MERS-CoV), have been widely acknowledged for several years, 10 the compounds derived from natural sources, e.g. plants and fungi, could have the potential to be a powerful anti-COVID-19 drug. In this review, we focused on four main categories of therapeutic strategies that aim to target the cellular machinery at each step of virus life cycle, starting from viral entry and replication to the release of viral progenies, as well as the RAAS which is a main target of the treatment of hypertension and has recently been proposed as another promising alternative in the treatment of COVID-19. The multiple potential therapeutic mechanisms, both specific and general, that could be capable of tackling COVID-19 infection are presented in Fig. 1 . The first therapeutic strategy targets on the mechanisms of virus entry in which the selective blockade of molecules that facilitates the internalization of virus into the host cells could be effective to prevent infection. Upon the binding of a virus surface spike (S) protein to a cellular receptor angiotensin-converting enzyme 2 (ACE2), the SARS-CoV-2 generally enters into target host cells via two primary routes; viral membrane fusion and the more common endocytic uptake. 11 The first entry mechanism is assisted by proteolytic activation of S protein by a host cell transmembrane protease serine 2 (TMPRSS2), which allows not only direct fusion of virus at the plasma membrane surface, but also release of viral genomic RNA into the cytoplasm. On the other hand, without the membrane bound protease TMPRSS2, the latter entry mechanism allows the whole viral particle to be uptaken via receptor-mediated endocytosis, before subsequently uncoated following the S protein cleavage by cathepsin L within the endosome, to unveil its RNA genome into the cell. The second and third therapeutic strategies focus on the inhibition of progeny virus production and release from infected cells. As far as the viral replication process is concerned, 12 it begins with the translation of released genome of SARS-CoV-2, a singlestranded (positive-sense) RNA of approximately 30 kb in length, into two precursor polyproteins, pp1a and pp1ab. Both are further cleaved by virus-encoded proteases into several non-structural proteins (nsps) including two key replicative enzymes: the nsp12-RNA-dependent RNA polymerase (RdRp) and the nsp13helicase, to form the replication-transcription complex (RTC) for synthesizing a full-length genomic RNA (replication) or a nested set of subgenomic mRNA (transcription). These mRNAs are translated into all relevant structural proteins, which together with the viral genome are subsequently assembled into new virions and finally released outside the cell through viroporin-mediated viral budding. 13 The last therapeutic strategy involves modulating the immune system with the RAAS which regulates blood pressure, fibrosis, and inflammation. In this system, angiotensin-converting enzyme (ACE) converts angiotensin I to angiotensin II which is then converted to lung-protective angiotensin-(1e7) by ACE2. The angiotensin-(1e7) is further recognized by its receptor, the G-protein coupled receptor Mas, to reduce blood pressure, fibrosis, and inflammation. 14 However, as SARS-CoV-2 enters the cells by binding to ACE2, the normal functions of ACE2 are then suppressed. Therefore, instead of converting to angiotensin-(1e7), the angiotensin II is largely bound to type 1 angiotensin II type 1 receptor (AT1R) which causing increased inflammation and other deleterious effects, particularly in the renal and cardiovascular systems. 15 3. Potential natural products as drug candidates against COVID-19 The data presented in this review were obtained from PubMed, Scopus and Google Scholar database up to May 2020. The terms of natural compound, natural product, plant and mushroom were individually searched along with the terms corresponding to each target molecule. Here, we summarize plant-and mushroomderived compounds that have been reported of antiviral activity with known therapeutic mechanisms specifically against SARS-CoV infection, performed by in vitro cell or non-cell based experiments but not in silico method, as potential candidates to be further researched. We also propose certain promising natural compounds targeting general mechanisms involved in coronavirus infection (see Fig. 1 ). Additionally, the reports on natural compounds against SARS-CoV with unidentified mechanism of action were included in this review. The S protein plays a pivotal role in the entry of coronaviruses into host cells by recognizing and binding to the ACE2 via multivalent bonds. 16 The attachment of S protein to ACE2 receptor leads to the fusion between the viral envelope and host cell membrane resulting in successful transfer of viral genome into infected cells. 17, 18 S protein is composed of two functional subunits, S1 and S2. The S1 is responsible for binding to the host cell receptor through the receptor binding domain (RDB), while the S2 causes fusion of the viral and cellular membranes. 19, 20 Sequence alignment results showed that the homology of the S protein RBD sequence between the beta coronaviruses SARS-CoV and SARS-CoV-2 is 76%. 21 A number of evidence revealed human ACE2 (hACE2) molecule as an entry receptor for both SARS-CoV and SARS-CoV-2 S proteins. 22e25 Notably, S protein of SARS-CoV-2 was found to exhibit greater affinity to the ACE2 receptor than that of SARS-CoV. 24 In addition, expression of ACE2 is ubiquitous with diverse functions, however its specific functions are demonstrated in several organs including lung, tongue, heart, kidney, gastrointestinal tract, pancreas and brain. 26, 27 Accordingly, multiple symptoms could be observed in COVID-19 patients. 27 Several observations have been reported that the use of hydroxychloroquine, an ACE2 FDA-approved antagonist, was able to reduce mortality rate in hospitalized COVID-19 patients. 28 Therefore, it is apparent that the S protein-hACE2 interaction complex is the most crucial target for searching appropriate inhibitors to inhibit entry of the virus in the host cell. Several natural compounds have been demonstrated their activity to inhibit SARS-CoV entry to the host cell as shown in Table 1 . According to the literature, an anthraquinone compound, emodin, showed the potency to inhibit viral infection by blocking the binding of SARS-CoV S protein to ACE2 in a dose-dependent manner. 29 The plant sources which are likely to contain emodin as their active constituent were also found effective in blocking SARS-CoV S protein and ACE2 interaction, with showing IC 50 values for aqueous extracts from the root of Rheum palmatum, the root and stem of Polygonum multiflorum, ranged from 1 to 10 mg/ml. 29 Another previous study using the high-throughput screening technique revealed more promising natural antiviral compounds consisted in the extracts from Chinese herbs. Those small herbal molecules could strongly bind to the SARS-CoV S2 protein and , and endocytic pathwayassociated proteins such as clathrin, the vacuolar-type H þ -ATPase (V-ATPase), and cathepsin L (❸), prevent the internalization of virus within the cell. Virus multiplication can be blocked through direct inhibition of proteolytic activity of two viral proteases, 3CL pro and PL pro (❹), and replicative activity of viral RTC components e.g., RdRp and helicase (❺), or indirect enzyme inhibition by increasing intracellular Zn 2þ concentration (❻). Silencing the expression and ion channel activity of viroporin 3a suppresses the release of viral particles from infected cells (❼). Overactivation of Ang II/AT1R axis which contributes to excessive inflammation, can be suppressed by blockade of ACE (❽) and AT1R (❾). 3CL pro , 3chymotrypsin-like protease; ACE2, angiotensin-converting enzyme 2; Ang, angiotensin; AT1R, angiotensin II type 1 receptor; E, envelope; MasR, mitochondrial assembly receptor; M, membrane; N, nucleocapsid; PL pro , papain-like protease; pp, polyprotein; RAAS, renin-angiotensin-aldosterone system; RdRp, RNA-dependent RNA polymerase; RTC, replicationtranscription complex; S, spike; TMPRSS2, transmembrane protease serine 2. Cell-based assay (LysoSensor Yellow/ Blue staining) 44 Inhibiting the SARS-CoV 3CL pro activity Cell-free assay (FRET) 84 Angelica keiskei IC 50 Cell-free assay (Fluorescence-based deubiquitination) Cell-free assay (Fluorescence-based deubiquitination) Cell-free assay (Fluorescence-based deubiquitination) 89 6-Geranyl-4 0 ,5,7-trihydroxy-3 0 ,5 0dimethoxyflavanone Flavonoid Paulownia tomentosa Cell-free assay (Fluorescence-based deubiquitination) 89 Broussochalcone A Chalcone Broussonetia papyrifera Cell-free assay (Fluorescence-based deubiquitination) 84 Broussochalcone B Chalcone Broussonetia papyrifera Cell-free assay (Fluorescence-based deubiquitination) 84 Cryptotanshinone Tanshinone Salvia miltiorrhiza Cell-free assay (Fluorescence-based deubiquitination) 51 Curcumin Polyphenol Curcuma longa a IC 50 Cell-free assay (using liposome model) 60 increased the uptake of Zn 2þ in both cell (2- fold increase at EC of 100 mM) and liposome model (8-fold increase at EC of 10 mM) Cell-based assay (Fluorescent Zn 2þ indicator) and cell-free assay (using liposome model) [62] Resveratrol Polyphenol Vitis vinifera a increased intracellular Zn 2þ level (7.5-fold increase at EC of 10 mM) inhibited the pseudovirus entry, possibly by interfering with the function of the S protein. 30 Recognized as a host trypsin-like serine protease, TMPRSS2 highly expressed in alveolar cells has been demonstrated to facilitate viral entry by priming of viral S protein. Inhibition of TMPRSS2 activity could prevent infection of coronaviruses including MERS-CoV, SARS-CoV and SARS-CoV-2. 31 Now, several synthetic drugs like camostat mesylate, nafamostat mesylate and bromhexine which are serine protease inhibitors showed potential to inhibit SARS-CoV-2 infection. 32e34 However, on the side of natural products, only few compounds were reported. Xanthoangelol G isolated from Angelica keiskei was reported to inhibit a trypsin-like serine protease with its IC 50 value of 51.6 mM. 35 Notably, in vitro cell-based and in vivo experiments are needed to be done for the development of anti-SARS-CoV-2 drugs. Clathrin-mediated endocytosis has been recognized as the primary cell entry route for multiple coronaviruses, including new emerging SARS-CoV-2, by utilizing the binding of viral S protein to host receptor ACE2 molecule. 36 After endocytosis into the target cell, the viral particle undergoes the cleavage of S protein mediated by a pH-dependent cysteine protease cathepsin L at an acidic endolysosomal pH (~3.0e6.5), which finally triggers membrane fusion between virus and endosome, followed by release of viral genetic material into the cytoplasm. Hence, targeting endocytic pathway-associated proteins are considered to be one of promising strategies for inhibiting SARS-CoV-2 entry. 37 Following this idea, Table 1 summarizes natural compounds that have been reported with inhibitory effects on the vacuolar-type H þ -ATPase (V-ATPase) activity, the expression and activity of cathepsins, or an increasing effect on lysosomal pH, which lead to impaired acidification and protein degradation of intracellular vesicles like endolysosome. Our search revealed that terpenes/terpenoids 38e41 and alkaloids 42e44 are two major classes of compounds acting through this strategy. In addition to individual compounds, some crude plant extracts have shown their potential for being developed as an anti-COVID-19 drug. The traditional Japanese herbal formulation named Maoto, prepared from a mixture of four plants (Ephedrae herba, Armeniacae semen, Cinnamomi cortex and Glycyrrhizae radix), was recently shown to inhibit endolysosomal acidification. 45 Zhuang et al. also demonstrated that butanol crude fraction from C. cortex was able to inhibit the clathrin-dependent endocytosis pathway as well as the infection of SARS-CoV using cell-based assays. 46 The 3CL pro is an enzyme that plays important role in replication of coronaviruses. It is responsible for the cleavage of polyproteins to functional proteins. Base on the protein structures, 3CL pro of SARS-CoV and SARS-CoV-2 show similarity of amino acid sequence at 96%, and both enzymes exhibit high conservation of active residues. 47 Therefore, small molecules with SAR-CoV 3CL pro inhibitory activity may also inhibit 3CL pro of SARS-CoV-2. Numerous studies have revealed for plant and mushroom derived natural compounds that could suppress SARS-CoV replication by blocking 3CL pro activity with IC 50 range from 8.3 to 92.4 mM in either cell-free or cellbased assays. Among them, hesperetin, a phenolic compound isolated from Isatis indigotica root exhibited the greatest inhibitory activity against SARS-CoV 3CL pro (IC 50 ¼ 8.3 mM) in an African green monkey kidney (Vero) cell line and this effective dose did not toxic to the cells (CC 50 ¼ 2.7 mM). 48 Other phytochemical classes that have shown promise in the inhibition of this enzyme are lignoid, terpenoid, tanshinone and chalcone with IC 50 less than 25 mM. 35,49e51 Interestingly, the lignoid savinin was able to reduce both viral replication (Selective index > 667) and cytopathic effect on SARS-CoV-infected Vero E6 cells. 49 The summary of bioactive compounds against SARS-CoV 3CL pro inhibitory activity is tabulated in Table 1 . Regarding to the similarity between 3CL pro of SARS-CoV and SARS-CoV-2, these natural compounds are interesting substances to screen as inhibitors of SARS-CoV-2 3CL pro activity furthermore. Similar to 3CL pro , the function of PL pro is essential for coronavirus replication by generating RTC through proteolytic processing of viral polyprotein. Hence, PL pro could be served as another attractive target of drug discovery for treatment of coronavirus infection, especially SARS-CoV-2. At present, there is no FDA approved PL pro inhibitor available, therefore identification of bioactive compounds from medicinal plants that specifically inhibit PL pro has been focused to develop a new class of anti-coronavirus drug. According to high similarity of protein sequences and active residues between SARS-CoV and SARS-CoV-2 PL pro (83%), 47 the compounds that have been reported as inhibitors of SARS-CoV PL pro may also be effective against SARS-CoV-2. The replication of full-length genomic RNA and the discontinuous transcription of subgenomic RNA transcripts are crucial for the production of new coronavirus particles inside the host cell. Both processes are mediated by the coronavirus RTC composed of multiple viral nsps including two key replicative enzymes like the RdRp (nsp12) and helicase (nsp13), 52 which are now considered as potential targets for COVID-19 therapy. Considering a strikingly high homology of nucleotide sequence, amino acid sequence and protein structure between SARS-CoV and SARS-CoV-2 RdRp, 53 the natural compounds with previous reports of inhibitory activities towards RdRp of SARS-CoV could also have the potential to suppress the activities of those enzymes of the SARS-CoV-2. It was shown that the water extract from Houttuynia cordata exhibited a dosedependent inhibition on SARS-CoV RdRp activity with the highest decrease by 74% in the treatment of 800 mg/mL. 54 The inhibitors of SARS-CoV helicase also serve as a potential drug candidate since this enzyme has a highly conserved sequence among coronaviruses and shares the similar structure to that of SARS-CoV-2. 52 Herein, three plant-derived bioactive compounds that could be natural inhibitors of SARS-CoV-2 helicase are listed in Table 1 . Zinc is an essential micronutrient that is required for various cellular metabolic processes, not only in human immunity but also in the replication of many viruses. 56 Although Zinc ion (Zn 2þ ) acts as a cofactor for several important viral enzymes such as RdRp, 3CL pro and PL pro , it is interesting that its high intracellular concentration was found to inhibit those enzyme activities of a variety of RNA viruses including SARS-CoV, 56e58 thus leading to subsequent decrease in the production of new virions. Therefore, Zn 2þ possesses antiviral properties through generating host immune responses and inhibiting viral replication. As of now, several researchers have suggested the use of Zn 2þ ionophore, a compound that stimulates cellular import of Zn 2þ (e.g., chloroquine and its derivatives), as a possible option for the treatment of COVID-19. 59 In Table 1 , we summarized some natural compounds with Zn 2þ ionophore activity. The most promising compound is epigallocatechin-3-gallate (EGCG), followed by quercetin, luteolin, tannic acid and resveratrol. 60e62 The viroporins are small, pore-forming, viral-encoded accessory proteins with ion channel activity that have been known to play an essential role in mediating several processes in the life cycle of many viruses, including coronaviruses. 63 Viroporin 3a functions are strongly involved in the regulation of viral budding and release from infected cells. 13 Interestingly, this protein was found unique to SARS-CoV and SARS-CoV-2 and not present in other known coronaviruses, 64 thus the viroporin 3a protein can be an important potential therapeutic target for COVID-19. Summary of natural compounds with inhibitory effect on viroporin 3a activity is presented in Table 1 Upon binding to SARS-CoV-2 S protein, the ACE2 function is downregulated which leads to increased angiotensin II level and overactivation of the AT1R signaling, causing the deleterious effects associated with excessive inflammation on several tissues. 67 Therefore, suppressing angiotensin II production by ACE inhibitors and blocking of AT1R by angiotensin-receptor blockers (ARBs) may be of benefit to ameliorate Ang II/AT1R-mediated inflammation in COVID-19 patients. Moreover, it was shown that an ARB could not only reduce AT1R activation, but also activate the AT2R, thus resulting in a production of vasodilation benefit. 68 Currently, ACE inhibitors and ARBs are commonly prescribed in COVID-19 patients with severe symptoms. Even though risks of the use of hypertensive drugs were concerned, accumulating evidence has not suggested the association between the drugs and worse clinical outcomes. 69, 70 Interestingly, a great number of natural compounds have been identified as potent ACE inhibitors and ARBs. Given that there are minimal side effects of using drugs from natural sources, those compounds with potential activity should be considered and investigated. Bioactive compounds derived from natural sources which possess ACE inhibitory activity are summarized in Table 1 . Among them, the excellent inhibitory properties against ACE were exerted by the phenolic caffeic acid and chlorogenic acid, and the stilbenoid hopeaphenol and vitisin A, with IC 50 less than 2 mM. 71, 72 These two stilbenoids were also found to be resveratrol tetramers exhibiting multifaceted properties including anti-inflammation 73 and antiviral infection as a potent inhibitor of hepatitis C virus helicase. 74 However, only few compounds have shown the ability to block AT1R which one of them is [6]-gingerol, the major bioactive compounds present in Zingiber officinale. According to the report by Liu and colleagues, it could inhibit AT1R activity with IC 50 of 8.2 mM as detected by cell-based calcium mobilization assay. 75 3.5. Anti-SARS-CoV natural compounds with unidentified mechanism of action Some natural occurring compounds have been reported their beneficial effect to inhibit SARS-CoV, even though their mechanisms of action have not yet been identified (Table 2) . Accordingly, the compounds from those previous studies might also have a potency to inhibit COVID-19 infection. Using HIV/SARS-CoV S pseudovirus and wild-type SARS-CoV, three anthocyanins derived from Cinnamomi cortex, cinnamtannin B1, procyanidin A2 and procyanidin B1, were reported their inhibitory activities against the infection of both viruses, but at least not through the inhibition of clathrin-mediated endocytosis. 46 This study also investigated the effects of some crude plant extracts and found that aqueous extract of Caryophylli Flos exhibited moderate inhibition to pseudovirus (IC 50 ¼ 58.8 mM) and wild-type virus (IC 50 ¼ 50.1 mM). 46 In addition, the natural alkaloid lycorine, isolated from Lycoris radiate, has been suggested as an anti-SARS-CoV compound with an IC 50 value of 15.7 nM. 121 Emerged as the most devastating viral infection in this era for the human race, the COVID-19 pandemic has introduced "new normal" for changing life as we recognize it. As numbers of new COVID-19 infected cases are rising globally, disruption of the transmission chain to minimize this spread is seriously unavoidable. This rise in COVID-19 infection is hardly disrupted unless its infective mechanisms including entry, replication and release, and modification of RAAS can be properly eliminated by humans. Certainly, we are waiting for effective strategies including drugs and vaccines to fight against COVID-19. Due to the unavailability of drugs to treat this infection, natural compounds are a main area of anti-COVID-19 research discovery. Our review suggests that 24 natural compounds have showed their potential actions on multiple therapeutic targets, which should be further explored for anti-COVID-19 plant/mushroom-based medicines (Fig. 2) . The classes of these phytochemical compounds include chalcones (n ¼ 7), flavonoids (n ¼ 5), tanshinones (n ¼ 5), phenolic acids (n ¼ 3), polyphenol (n ¼ 1), anthraquinone (n ¼ 1), diarylheptanoid (n ¼ 1) and biphenylpropanoid (n ¼ 1). Among them, a natural flavonoid quercetin is found as a lead candidate with its ability on the virus side to inhibit SARS-CoV S protein-ACE2 interaction, viral protease and helicase activities, as well as on the host cell side to inhibit ACE activity and increase intracellular zinc level, thus making it very promising to reduce the disease burden. Although it is previously speculated that certain ACE inhibitors with an increased activity of ACE2 receptor may indeed enhance viral infectivity, recent studies revealed no substantial association between increased risks of infection and ACE inhibitor medications. 69, 70 Therefore, it is worth noting that many potential mechanisms of anti-COVID-19 natural agents are required to carefully and substantially investigated. Together with proper proactive investments, it is our great hope that qualified natural compound-based medicines from promising leads described here will be developed as anti-COVID-19 soon to benefit the human race in this "new normal" era. Emerging Infectious Disease, Viral Infection of Respiratory System, Severe Acute Respiratory Syndrome Coronavirus, Cell culture, Molecular Biology, Traditional herbal medicine, Natural Product Analysis. The authors declare that they have no conflict of interest. Novel Coronavirus e China A novel coronavirus from patients with pneumonia in China Clinical features of patients infected with 2019 novel coronavirus in Wuhan Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) Hydroxychloroquine in patients with COVID-19: a systematic review and meta-analysis Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base The antiviral and coronavirus-host protein pathways inhibiting properties of herbs and natural compounds -additional weapons in the fight against the COVID-19 pandemic? Journal of traditional and complementary medicine Dietary therapy and herbal medicine for COVID-19 prevention: a review and perspective Antiviral natural products and herbal medicines SARS coronavirus entry into host cells through a novel clathrin-and caveolae-independent endocytic pathway From SARS to MERS, thrusting coronaviruses into the spotlight Severe acute respiratory syndrome-associated coronavirus 3a protein forms an ion channel and modulates virus release ACE2 (Angiotensin-Converting enzyme 2), COVID-19, and ACE inhibitor and Ang II (angiotensin II) receptor blocker use during the pandemic: the pediatric perspective Urgent need for evaluating agonists of angiotensin-(1-7)/Mas receptor axis for treating patients with COVID-19 Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor Structural insights into coronavirus entry Structure of SARS coronavirus spike receptor-binding domain complexed with receptor Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Receptor recognition by the novel coronavirus from wuhan: an analysis based on decade-long structural studies of SARS coronavirus Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation Structure analysis of the receptor binding of 2019-nCoV Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis SARS-CoV-2, ACE2 expression, and systemic organ invasion Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: findings from the observational multicentre Italian CORIST study Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells Candidate drugs against SARS-CoV-2 and COVID-19 SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection Journal of Traditional and Complementary Medicine xxx (xxxx) xxx inhibit cysteine proteases of SARS-CoV Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19 Block of vesicular stomatitis virus endocytic and exocytic pathways by 1-cinnamoyl-3,11-dihydroxymeliacarpin, a tetranortriterpenoid of natural origin The cycloartane triterpenoid ADCX impairs autophagic degradation through Akt overactivation and promotes apoptotic cell death in multidrug-resistant HepG2/ADM cells Leelamine mediates cancer cell death through inhibition of intracellular cholesterol transport Myrtenal-induced V-ATPase inhibition -a toxicity mechanism behind tumor cell death and suppressed migration and invasion in melanoma Natural autophagy blockers, dauricine (DAC) and daurisoline (DAS), sensitize cancer cells to camptothecin-induced toxicity Matrine, a novel autophagy inhibitor, blocks trafficking and the proteolytic activation of lysosomal proteases. Carcinogenesis Tetrandrine blocks autophagic flux and induces apoptosis via energetic impairment in cancer cells Maoto, a traditional Japanese herbal medicine, inhibits uncoating of influenza virus. Evid base Compl Alternative Med : eCAM Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus Triterpene and sterol derivatives from the roots of Breynia fruticosa Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV Immunomodulatory and anti-SARS activities of Houttuynia cordata Immunomodulatory activities of the herbal formula Kwan Du Bu Fei Dang in healthy subjects: a randomised, doubleblind, placebo-controlled study. Hong Kong medical journal ¼ Xianggang yi xue za zhi The role of zinc in antiviral immunity Zn(2þ) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture Zinc salts block hepatitis E virus replication by inhibiting the activity of viral RNA-dependent RNA polymerase Can Zn Be a critical element in COVID-19 treatment? A simple liposome assay for the screening of zinc ionophore activity of polyphenols Effect of resveratrol and zinc on intracellular zinc status in normal human prostate epithelial cells Zinc ionophore activity of quercetin and epigallocatechin-gallate: from Hepa 1-6 cells to a liposome model Viral membrane channels: role and function in the virus life cycle Identification of a novel protein 3a from severe acute respiratory syndrome coronavirus Kaempferol derivatives as antiviral drugs against the 3a channel protein of coronavirus Coronaviral Ion Channels as Target for Chinese Herbal Medicine Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: therapeutic implications Renin-angiotensin-aldosterone system and COVID-19 infection Renin-angiotensinaldosterone system blockers and the risk of covid-19 Renin-angiotensin-aldosterone system inhibitors and risk of covid-19 Antioxidant, antidiabetic, and antihypertensive properties of echinacea purpurea flower extract and caffeic acid derivatives using in vitro models Screening and profiling stilbene-type natural products with angiotensin-converting enzyme inhibitory activity from Ampelopsis brevipedunculata var. hancei (Planch.) Rehder Vitisin A suppresses LPS-induced NO production by inhibiting ERK, p38, and NF-kappaB activation in RAW 264.7 cells Identification of a resveratrol tetramer as a potent inhibitor of hepatitis C virus helicase gingerol: a novel AT₁ antagonist for the treatment of cardiovascular disease Alantolactone induces apoptosis and improves chemosensitivity of pancreatic cancer cells by impairment of autophagylysosome pathway via targeting TFEB Cleistanthin A inhibits the invasion and metastasis of human melanoma cells by inhibiting the expression of matrix metallopeptidase-2 and -9 Synthesis and identification of cytotoxic diphyllin glycosides as vacuolar H(þ)-ATPase inhibitors Effects of diphyllin as a novel V-ATPase inhibitor on TE-1 and ECA-109 cells Inhibition of autophagosome-lysosome fusion by ginsenoside Ro via the ESR2-NCF1-ROS pathway sensitizes esophageal cancer cells to 5-fluorouracil-induced cell death via the CHEK1-mediated DNA damage checkpoint Icariside II-induced mitochondrion and lysosome mediated apoptosis is counterbalanced by an autophagic salvage response in hepatoblastoma The natural compound oblongifolin C inhibits autophagic flux and enhances antitumor efficacy of nutrient deprivation Synergistic anti-breast cancer effect of pulsatilla saponin D and camptothecin through interrupting autophagiclysosomal function and promoting p62-mediated ubiquitinated protein aggregation Evaluation of polyphenols from Broussonetia papyrifera as coronavirus protease inhibitors Diarylheptanoids from Alnus japonica inhibit papain-like protease of severe acute respiratory syndrome coronavirus Comparative evaluation of two structurally related flavonoids, isoliquiritigenin and liquiritigenin, for their oral infection therapeutic potential Anti-inflammatory and free radial scavenging activities of the constituents isolated from Machilus zuihoensis Binding interaction of quercetin-3-b-galactoside and its synthetic derivatives with SARS-CoV 3CLpro: structureeactivity relationship studies reveal salient pharmacophore features Geranylated flavonoids displaying SARS-CoV papain-like protease inhibition from the fruits of Paulownia tomentosa Phenolic phytochemical displaying SARS-CoV papain-like protease inhibition from the seeds of Psoralea corylifolia Magnetic purification of curcumin from Curcuma longa rhizome by novel naked maghemite nanoparticles Isoflavone dimers and other bioactive constituents from the figs of Ficus mucuso Papain-like protease (PLpro) inhibitory effects of cinnamic amides from Tribulus terrestris fruits Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13 Investigation of the pharmacophore space of Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) NTPase/helicase by dihydroxychromone derivatives Antiviral activity of the zinc ionophores pyrithione and hinokitiol against picornavirus infections Emodin inhibits current through SARS-associated coronavirus 3a protein Novel RAS inhibitor 25-O-methylalisol F attenuates epithelial-to-mesenchymal transition and tubulointerstitial fibrosis by selectively inhibiting TGF-beta-mediated Smad3 phosphorylation ACE and platelet aggregation inhibitors from Tamarix hohenackeri Bunge (host plant of Herba Cistanches) growing in Xinjiang Angiotensin-I-Converting enzyme inhibitory activity of coumarins from Angelica decursiva Ethanolic extracts and isolated compounds from small-leaf grape (Vitis thunbergii var. taiwaniana) with antihypertensive activities Antioxidant and angiotensin converting enzyme (ACE) inhibitory activities of ethanol extract and pure flavonoids from Adinandra nitida leaves Top-down targeted metabolomics reveals a sulfur-containing metabolite with inhibitory activity against angiotensin-converting enzyme in Asparagus officinalis Bioassay-guided preparative separation of angiotensin-converting enzyme inhibitory C-flavone glycosides from Desmodium styracifolium by recycling complexation high-speed countercurrent chromatography Antihypertensive properties of flavonoid-rich apple peel extract New phenolic compounds from Coreopsis tinctoria Nutt. and their antioxidant and angiotensin i-converting enzyme inhibitory activities Curcumin and its carbocyclic analogs: structure-activity in relation to antioxidant and selected biological properties Inhibition of angiotensin convertin enzyme (ACE) activity by the anthocyanins delphinidin-and cyanidin-3-O-sambubiosides from Hibiscus sabdariffa Flavonoids from the buds of Rosa damascena inhibit the activity of 3-hydroxy-3-methylglutaryl-coenzyme a reductase and angiotensin I-converting enzyme Inhibitory activities of Cassia tora and its anthraquinone constituents on angiotensin-converting enzyme Mechanisms underlying the diuretic effects of Tropaeolum majus L. extracts and its main component isoquercitrin Identification of a new angiotensin-converting enzyme (ACE) inhibitor from Thai edible plants Activity-guided discovery of (S)-malic acid 1'-O-beta-gentiobioside as an angiotensin I-converting enzyme inhibitor in lettuce (Lactuca sativa) Phenolic-linked biochemical rationale for the anti-diabetic properties of Swertia chirayita Polyphenols composition from leaves of Cuphea spp. and inhibitor potential Spermidine derivatives in lulo (solanum quitoense lam.) fruit: sensory (taste) versus biofunctional (ACE-Inhibition) properties Evaluation of angiotensin converting enzyme inhibitors by SPR biosensor and theoretical studies Isolation, identification and molecular docking studies of a new isolated compound, from Onopordon acanthium: a novel angiotensin converting enzyme (ACE) inhibitor Antioxidant potential and angiotensin-converting enzyme (ACE) inhibitory activity of orotic acid-loaded gum Arabic nanoparticles Angiotensin-converting enzyme inhibitory effects by plant phenolic compounds: a study of structure activity relationships Identification of natural compounds with antiviral activities against SARS-associated coronavirus This work was partially supported by Grant for Research, Ratchadaphiseksomphot Endowment Fund, Chulalongkorn University, Thailand.